Epidemiologic evidence of proteus mirabilis infection in patients with rheumatoid arthritis:A systematic evaluation and Meta-analysis of included global controlled studies
10.3969/j.issn.1673-9701.2025.18.005
- VernacularTitle:RA患者奇异变形杆菌感染的流行病学证据——一项纳入全球对照研究的Meta分析与系统评价
- Author:
Jiawei ZHANG
1
;
Li JI
;
Guoyong DING
;
Shuman LIU
;
Mengyun WU
;
Xue ZHANG
;
Aihong ZHOU
Author Information
1. 山东第一医科大学第二附属医院风湿免疫科,山东泰安 271000
- Publication Type:Journal Article
- Keywords:
Rheumatoid arthritis;
Proteus mirabilis;
Controlled studies;
Urinary tract infections
- From:
China Modern Doctor
2025;63(18):18-24
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically evaluate the level of proteus mirabilis(PM)infection in patients with rheumatoid arthritis(RA)and to investigate its potential association with the development of RA.Methods Based on Meta-analysis of observational studies in epidemiology and preferred reporting items for systematic review and Meta-analysis guide,a comprehensive search of PubMed,Web of Science and Embase databases was conducted to screen relevant literature published up to December 2024 for studies comparing the levels of anti-PM antibodies between RA patients and healthy populations,and the quality of the included studies was assessed by using the Newcastle-Ottawa scale.Heterogeneity among studies was assessed by Q-test and I2-test,and accordingly,fixed-effects or random-effects models were selected,and the robustness of the results was assessed by sensitivity analyses,Begg's test,and clipping and patching method.Results Finally,18 eligible articles were included,involving 753 RA patients and 716 healthy controls.The total antibody levels[weighted mean difference(WMD)=0.86,95％CI:0.38-1.34,I2=98.3％,P=0.000]and IgA antibody levels(WMD=0.17,95％CI:0.06-0.28,I2=96.7％,P=0.000)of RA patients were higher than those of healthy controls,and subgroup analyses revealed significant heterogeneity among geographic regions and testing methods.Conclusion Prevention and treatment of PM infections may be a complementary strategy for RA management and provide evidence-based support for the"PM antigen-genitourinary tract mucosa-autoimmunity"pathology hypothesis.
